MA45307A - Procédés de réduction ou de prévention des dommages à l'intima provoqués par une stimulation mécanique de cellules endothéliales - Google Patents

Procédés de réduction ou de prévention des dommages à l'intima provoqués par une stimulation mécanique de cellules endothéliales

Info

Publication number
MA45307A
MA45307A MA045307A MA45307A MA45307A MA 45307 A MA45307 A MA 45307A MA 045307 A MA045307 A MA 045307A MA 45307 A MA45307 A MA 45307A MA 45307 A MA45307 A MA 45307A
Authority
MA
Morocco
Prior art keywords
preventing
reducing
methods
endothelial cells
damage caused
Prior art date
Application number
MA045307A
Other languages
English (en)
Inventor
Sven Jacobson
J Marc Simard
Original Assignee
Biogen Chesapeake Llc
The Usa As Represented By The Dept Of Veterans Affairs
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc, The Usa As Represented By The Dept Of Veterans Affairs, Univ Maryland filed Critical Biogen Chesapeake Llc
Publication of MA45307A publication Critical patent/MA45307A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/104—Balloon catheters used for angioplasty
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045307A 2015-05-29 2016-05-25 Procédés de réduction ou de prévention des dommages à l'intima provoqués par une stimulation mécanique de cellules endothéliales MA45307A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562168589P 2015-05-29 2015-05-29

Publications (1)

Publication Number Publication Date
MA45307A true MA45307A (fr) 2018-04-11

Family

ID=57441652

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045307A MA45307A (fr) 2015-05-29 2016-05-25 Procédés de réduction ou de prévention des dommages à l'intima provoqués par une stimulation mécanique de cellules endothéliales

Country Status (14)

Country Link
US (1) US10900040B2 (fr)
EP (1) EP3302514B1 (fr)
JP (2) JP6973752B2 (fr)
KR (1) KR102618123B1 (fr)
CN (1) CN108348567B (fr)
AU (1) AU2016271576B2 (fr)
CA (1) CA2988417C (fr)
EA (1) EA038398B1 (fr)
ES (1) ES2927482T3 (fr)
HK (1) HK1252532A1 (fr)
IL (1) IL255875A (fr)
MA (1) MA45307A (fr)
MX (1) MX2017015297A (fr)
WO (1) WO2016196113A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
US9949991B2 (en) 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057651A1 (fr) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
WO2006036278A2 (fr) * 2004-09-18 2006-04-06 University Of Maryland, Baltimore Agents therapeutiques ciblant le canal ncca-atp et leurs methodes d'utilisation
US20100092469A1 (en) * 2007-02-09 2010-04-15 Simard J Marc Antagonists of a non-selective cation channel in neural cells
CA2974689C (fr) * 2007-06-22 2020-02-25 The United States Of America As Represented By The Department Of Veters Affairs Inhibiteurs de canaux nc<sb>ca-atp</sb> pour therapie
SI2868315T1 (sl) 2007-12-04 2017-10-30 Biogen Chesapeake Llc Izboljšane formulacije in metode za liofilizacijo in liofilizate zagotovljene z le-to
WO2012012347A2 (fr) 2010-07-19 2012-01-26 Remedy Pharmaceuticals, Inc. Procédés d'administration par voie intraveineuse de glyburide et autres médicaments

Also Published As

Publication number Publication date
EA201792569A1 (ru) 2018-04-30
IL255875A (en) 2018-01-31
KR20180035741A (ko) 2018-04-06
JP2018516981A (ja) 2018-06-28
EP3302514B1 (fr) 2022-07-06
US20180155727A1 (en) 2018-06-07
HK1252532A1 (zh) 2019-05-31
EA038398B1 (ru) 2021-08-23
EP3302514A4 (fr) 2019-04-24
US10900040B2 (en) 2021-01-26
MX2017015297A (es) 2018-06-19
CA2988417C (fr) 2022-10-11
JP2021167335A (ja) 2021-10-21
CA2988417A1 (fr) 2016-12-08
KR102618123B1 (ko) 2023-12-27
JP6973752B2 (ja) 2021-12-01
WO2016196113A1 (fr) 2016-12-08
CN108348567A (zh) 2018-07-31
EP3302514A1 (fr) 2018-04-11
AU2016271576A1 (en) 2018-01-04
ES2927482T3 (es) 2022-11-07
AU2016271576B2 (en) 2021-10-07
CN108348567B (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
DK3360558T3 (da) Sammensætninger omfattende bakteriestammer
DK3369425T3 (da) Sammensætninger omfattende bakteriestammer
DK3650033T3 (da) Sammensætninger omfattende bakteriestammer
DK3368541T3 (da) Sammensætninger og metoder til inhibiering af arginaseaktivitet
DK3209691T3 (da) Sammensætninger til inducering af differentiering af myeloid-afledt suppresorcelle til behandling af cancer og infektiøse sygdomme
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3274430T3 (da) Mikroalgesammensætninger og deres anvendelser
EA201691421A1 (ru) Гетероарилы и их применение
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3394272T5 (da) Sammensætninger og fremgangsmåder til effektiv målretning af transgener
DK3341379T3 (da) EZH2-hæmmere
FR3028909B3 (fr) Structure amelioree d&#39;actionneur lineaire
DK3600363T3 (da) Sammensætninger omfattende bakteriestammer
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3638271T3 (da) Sammensætninger omfattende bakteriestammer
DK3122743T3 (da) Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
DK3174861T3 (da) Substituerede bicykliske dihydropyrimidinoner og deres anvendelse som inhibitorer af neutrofil elastaseaktivitet
DK3643176T3 (da) Systemer og fremgangsmåder til forbedring af organ- eller vævsfunktion og levetiden af organ- eller vævstransplantat